Synakis has created a vitreous substitute to transform the treatment of retinal detachment which use vitreous substitutes.
Synakis has raised $1.9M in total funding. The most recent round was Seed. The last funding was announced in May 2026.
Synakis's investors include Ontario Centre of Innovation, UTEST.
Synakis is headquartered in Toronto, Canada.
Synakis has created a vitreous substitute to transform the treatment of retinal detachment which use vitreous substitutes.
Synakis is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Synakis — Funding & Investors." VCBacked, May 11, 2026, https://www.vcbacked.co/company/synakis. Accessed October 4, 2026.
VCBacked. (2026). Synakis — Funding & Investors. Retrieved October 4, 2026, from https://www.vcbacked.co/company/synakis
{{cite web |title=Synakis — Funding & Investors |url=https://www.vcbacked.co/company/synakis |website=VCBacked |access-date=October 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated